Regeneron expects FDA decision on higher-dose Eylea this year
By Khushi Mandowara (Reuters) -Regeneron Pharmaceuticals expects a U.S. decision on a higher-dose version of its blockbuster eye disease drug Eylea in the third quarter, much earlier than market expectations, sending its shares up 5% on Thursday. The U.S. Food and Drug Administration declined to approve the higher-dose version in June following an inspection at third-party manufacturer Catalent. Regeneron said it has been submitting manufacturing data required by the FDA […]